

August 22, 2017

Dear Valued B. Braun Customer,

B. Braun Medical Inc. has been and continues to be focused on increasing the availability of sterile IV solutions that are critical for patient care. As demand for these products has increased, we've been investing in equipment upgrades, improved processes, and a new manufacturing location to introduce new supply to the marketplace.

Throughout 2017, we have been planning for a plant shutdown to do critical maintenance work at the end of the year. However, unplanned production interruptions have resulted in significant decreases in supply of product necessary to meet current demands of our customers. The December shutdown will further strain our inventory levels.

Some customers have already experienced backorders, and we anticipate that this situation will continue through the first quarter of 2018. We are doing our best to anticipate customer needs and maximize production output.

Given our current and anticipated supply situation, we advise you to immediately start sourcing a portion of your product demand from alternative manufacturers for all PAB® (SVP) and the following four Excel® codes (L7500, L8000, L8001 and L8002) through the first quarter of 2018. Starting with the October allocation period, allocations will be adjusted as needed and the final percentage will be communicated by your sales representative. Please reference the list of affected products on the following page.

We are diligently working to resolve the causes of the current production interruptions and are prioritizing production based on our inventory and distributor inventory levels. Improvements are expected over the next several months, but we do not anticipate that this will fully support our customer demand in the short term.

We understand the disruption that this has on our customers and sincerely apologize. With patient care as the top priority for both of us, we will be communicating to you on a regular basis to provide you with timely information as we work through this difficult time.

We are confident that our long-term investments in expanded production facilities will result in equally long-term benefits. We appreciate your support and want you to know that we are dedicated to you, your patients and the healthcare industry.

Information regarding drug products that are experiencing supply disruptions in the US is communicated by manufacturers to the FDA and posted on the FDA web page. For specific information regarding drug supply issues, please refer to the following link: <https://www.fda.gov/Drugs/DrugSafety/DrugShortages>.

Sincerely,



Tom Sutton
Vice President, Marketing

B. Braun Medical Inc. advises the immediate sourcing of a portion of your demand of the following products from alternative manufacturers through the first quarter of 2018.

Product Code	NDC #	B. Braun Product	Size (mL)	Container
L7500	0264-7750-00	Lactated Ringer's Injection USP	1000	Excel
L8000	0264-7800-00	0.9% Sodium Chloride Injection USP	1000	Excel
L8001	0264-7800-10	0.9% Sodium Chloride Injection USP	500	Excel
L8002	0264-7800-20	0.9% Sodium Chloride Injection USP	250	Excel
D5353-5224	0264-5535-32	Metronidazole Injection USP 500 mg (5 mg/mL)	100	PAB
S5104-5264	0264-1510-32	5% Dextrose Injection USP	100 fill in 150	PAB
S5104-5384	0264-1510-31	5% Dextrose Injection USP	50 fill in 100	PAB
S5104-5410*	0264-1510-36	5% Dextrose Injection USP	25 fill in 100	PAB
S8004-5264	0264-1800-32	0.9% Sodium Chloride Injection USP	100 fill in 150	PAB
S8004-5384	0264-1800-31	0.9% Sodium Chloride Injection USP	50 fill in 100	PAB
S8004-5410	0264-1800-36	0.9% Sodium Chloride Injection USP	25 fill in 100	PAB
5904-52		Empty PAB	150 mL	PAB

*Currently not available.